Pioneering Innovation in Delaware and Beyond

CONTRIBUTED BY INCYTE

AT INCYTE, we believe every challenge is a chance for a breakthrough.

Since the start, our global headquarters in Wilmington, Del., has been a hub for biopharmaceutical innovation. We take pride in our role in the U.S. pharmaceutical sector, which is responsible for more than 50% of the world’s new drug discoveries, and have maintained a clear mission to make a meaningful difference for patients around the world through our work.

The scientists, chemists, and biologists who began this journey with us shared the passion and perseverance that would — over the span of more than 20 years — provide nine first-of-its-kind treatments to patients around the world and grow Incyte into a global organization with more than 2,700 employees.

We recognize the transformative power of research in shaping the future of medicine. Our research focuses on expanding our portfolio and advancing treatments where we can make the greatest impact. Today, we have a robust portfolio of treatments across oncology and inflammation and autoimmunity, including dermatology, and our passion for innovation is stronger than ever. To date, our commercialized medicines have treated more than two million patients.

We are committed to accelerating research and development opportunities and understand that innovation thrives through collaboration. We actively partner with leading universities, pharmaceutical and biotechnology companies, and patient advocacy organizations to help amplify our impact across dermatology, oncology, and beyond.

We’re also using advanced technologies, including artificial intelligence, to enhance research efficiency and regulatory processes in an effort to bring solutions to patients faster — and we are committed to responsibly using these tools to address areas of critical health care importance. With each discovery, we hope to be one step closer to a future where diseases that once seemed insurmountable are met with effective, innovative solutions.